Relmada Therapeutics RLMD
NASDAQ RLMD
$3.27 -0.02 (-0.61%)
At close: Oct 23, 2026 · 4:00 PM EDT

Relmada Therapeutics (RLMD) Return on Sales [ROS] (2012 - 2023)

Updated

Relmada Therapeutics (RLMD) reported Return on Sales [ROS] of -877.66% for FY2013, down 725.89 percentage points from -151.77% in FY2012.

Analysis

Relmada Therapeutics (RLMD) Return on Sales [ROS] (2012 - 2023) Analysis & Trends

  • According to Business Quant data, Return on Sales [ROS] came in at -151.77% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 24.35%
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 37.86%
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn -3.52%
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 32.97%
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 20.57%
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 34.95%
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -133.21%
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 28.37%
10 Relmada Therapeutics 348.81 Mn -209.78 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -2,130.62%
Sep 30, 2023 -1,717.26%
Jun 30, 2023 -1,908.95%
Mar 31, 2023 -5,204.74%
Dec 31, 2022 -3,579.66%
Sep 30, 2022 -14,564.87%
Jun 30, 2022 -11,051.05%
Mar 31, 2022 -12,160.73%
Dec 31, 2021 -95,047.20%
Dec 31, 2020 -9,329.66%
Sep 30, 2020 -4,729.86%
Sep 30, 2019 -9,777.96%
Mar 31, 2019 -16,952.16%
Dec 31, 2017 -2,694.77%
Sep 30, 2017 -177.52%
Jun 30, 2017 -865,477.67%
Mar 31, 2017 -482,653.70%
Dec 31, 2016 -623,014.39%
Sep 30, 2016 -882,762.38%
Jun 30, 2016 -163,632.54%
API Access

Relmada Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=RLMD&period=max&api_key=YOUR_API_KEY